Associations of Blood Levels of PCB, HCHs, and HCB with Numbers of Lymphocyte Subpopulations, in Vitro Lymphocyte Response, Plasma Cytokine Levels, and Immunoglobulin Autoantibodies.

Pentachlorophenol (PCP), hexachlorocydohexane-[Alpha], -[Beta], and -[Gamma] (HCH-[Alpha], -[Beta], and -[Gamma]), polychlorinated biphenyls (PCBs), and hexachlorobenzene (HCB) are widely distributed industrial chemicals. They are suspected to induce immunologic impairments in exposed individuals. We examined dose-response relationships of blood levels of these chemicals with cellular (numbers of lymphocyte subpopulations, in vitro lymphocyte response) or humoral (plasma cytokine levels, immunoglobulin autoantibodies) immunologic dysfunctions. We studied 146 patients who had been occupationally exposed primarily to PCBs for more than 6 months. Lymphocyte subpopulations, in vitro responses to mitogens and allogeneic stimulator cells, plasma neopterin, cytokines, soluble cytokine receptors, soluble adhesion molecules, anti-Ig autoantibodies, and liver transaminases were determined. Blood levels of the different compounds were strongly correlated with one another. There were only weak dose-response relationships between blood levels of PCBs with cellular immune parameters, and of HCHs and HCB with humoral immune parameters. An exception was the statistically significant negative association of HCB with interferon-[Gamma] (IFN-[Gamma]), indicating that HCB has a significant impact on Th1 lymphocytes. Patients with HCB blood levels above the mean of 1,109 ng/L more often had undetectable IFN-[Gamma] blood levels than patients below the mean. Patients with increased PCB 138 ([is greater than] 710 ng/L) had more frequently undetectable inteleukin-4 blood levels than patients with PCB 138 below the mean, and patients with increased PCB 101 ([is greater than] 31 ng/L) more often had low DR+ cell counts in the blood ([is less than] 190/[micro]L) than patients with PCB 101 below the mean. To assess possible cumulative effects, we compared patients who had blood levels of all compounds below background with patients who had blood levels of all compounds above background. Patients with low or absent blood levels of the compounds studied had higher IFN-[Gamma] plasma levels, providing some evidence for a cumulative effect of several weakly active compounds. In conclusion, exposure to PCBs, HCB, or HCHs is associated with weak immunologic abnormalities. These results contrast with those obtained in earlier studies of blood levels of PCP, which showed a strong dose-dependent relationship with immunologic impairments. Our data suggest that long-term exposure of patients to HCB suppresses IFN-[Gamma] production. Key words: cytokines, hexachlorobenzene, hexachlorocyclohexane, immune function, lymphocytes, polychlorinated biphenyls, Environ Health Perspect 109:173-178 (2001). [Online 25 January 2001]

http://ehpnet1.niehs.nih.gov/docs/2001/ 109p173-178daniel/abstract.html

Pentachlorophenol (PCP), hexaehlorocyclohexane-[Alpha], -[Beta], and -[Gamma] (HCH-[Alpha], -[Beta], and -[Gamma]), polychlorinated biphenyls (PCBs), and hexachlorobenzene (HCB) are widely distributed industrial chemicals. PCBs are used as components of mobile oils, elastic sealing compounds, dielectric fluids in older transformers, heat exchangers, paints and printing inks, and pesticide extenders and protection colors for concrete (1-3). The fungicidal chemicals PCP and HCH were used in wood preservatives. PCP was banned in Germany in 1989, and the use of HCH-[Gamma] in pesticides was strongly reduced since 1991 (4). HCB is an organochlorine fungicide and is also used as a softening agent for plastics (5). PCBs are inert, lipid-soluble molecules and tend to accumulate in food chains in animals such as fish (6). PCBs accumulate in the human body, and their blood levels can be measured (2,7-10). In cell cultures as well as in animal experiments, all of these substances were toxic for lymphocytes in many studies (11-38), with some notable exceptions (39-43). Although there are reports of immunologic dysfunctions in patients with high exposure to these compounds (44-48), it is controversial whether the chemicals are toxic for humans. The compounds occur as mixtures, and studies on their possible interactive effects are therefore important. In previous studies we demonstrated a suppressive effect of PCP blood levels of [is greater than] 10 [micro]g/L on certain cellular and humoral immune parameters (38,49). To avoid an interference of high PCP levels, we excluded patients with PCP blood levels [is greater than] 10 [micro]g/L from the present analysis.

Materials and Methods

Patients. From 1992 to 1998 blood levels of PCP, PCBs, HCHs, and HCB were determined in 146 patients. Immune parameters were measured in 141 individuals. Two patients were investigated in 1992, 2 in 1993, 6 in 1994, 10 in 1995, 30 in 1996, 44 in 1997, and 52 in 1998. We studied 12 patients at least twice during a mean time interval of 936 days. In these patients, only the results of the last determination were used for statistical analysis. The patients had various clinical symptoms: 82% of the patients complained about a lack of mental concentration, 80% about rapid exhaustion, 50% had frequent common cold diseases, 39% had bronchitis, 14% experienced sleeplessness, 8% had irritations of mucous membranes of the throat and nose, 7% complained about general fatigue, and 2% about nausea. These clinical symptoms are in accordance with other reports of PCP-(50,51) and PCB-exposed patients (52,53). As determined by a questionnaire, 144 of 146 patients in the study were nonsmokers at the time of the investigation because they tried to avoid any contact with pollutants. The mean ([+ or -] 1 SD) age of the, patients was 46.8 [+ or -] 12.5 years (range, 8.6-74.2 years; [is less than or equal to] 18 years, n = 3; [is less than or equal to] 30 years, n = 9; [is less than or equal to] 40 years, n = 36; [is less than or equal to] 50 years, n = 87; [is less than or equal to] 60 years, n = 124); 71 were male and 75 were female. Patients with chronic diseases such as hepatitis B virus infection, renal failure, diabetes mellitus, or rheumatism were excluded from the study. The patients were occupationally exposed to PCBs for more than 6 months. Most of them were teachers, construction workers, or telecommunication technicians who were exposed to PCBs in schools, building sites, or factories. Ninety percent of the patients were exposed to PCBs for more than 20 years. Half of the patients were still exposed at the time of investigation. We did not determine blood levels of chemicals in controls.

Determination of plasma cytokines, soluble cytokine receptors, soluble cytokine receptor antagonists, and soluble adhesion molecules. Values obtained in 40 healthy controls are given in Table 1. Interleukin (IL)-1[Alpha], IL-1[Beta], soluble interleukin receptor antagonist (sIL-[1]RA), IL-2, IL-3, IL-4, IL-6, sIL-6R, IL-8, transforming growth factor (TGF)-[[Beta].sub.2], and tumor necrosis factor (TNF)-[Alpha] were measured by ELISA using Quantikine kits (R&D Systems, Firma Biermann, Bad Nauheim, Germany), soluble intercellular adhesion molecule (sICAM)-1 with Cellfree kits (T Cell Diagnostics, Biermann), sIL-2R with Immunotech kits (Dianova, Hamburg, Germany), interferon (IFN)-[Gamma] with HBT kits (Holland Biotechnology BV, Biermann), and IL-10 with Cytoscreen kits (Laboserv, Giessen, Germany). Plasma was snap frozen within 2 hr after blood was drawn and stored at -30 [degrees] C until testing.

Table 1. Mean values for studied parameters in
control subjects.

Parameter                   Mean [+ or -] SD

IL-1[Alpha]                 0 [+ or -] 0 pg/mL
IL-1[Beta]                  0 [+ or -] 1 pg/mL
sIL-1RA                   670 [+ or -] 1,164 pg/mL
IL-2                       24 [+ or -] 38 pg/mL
sIL-2R                  2,085 [+ or -] 2,126 pg/mL
IL-3                       27 [+ or -] 50 pg/mL
IL-4                        6 [+ or -] 17 pg/mL
IL-6                        2 [+ or -] 12 pg/mL
sIL-6R                 28,212 [+ or -] 7,836 pg/mL
IL-8                       51 [+ or -] 128 pg/mL
IL-10                       0 [+ or -] 1 pg/mL
TGF-[[Beta].sub.2]          4 [+ or -] 7 pg/mL
IFN-[Gamma]               383 [+ or -] 859 ng/mL
sICAM-1                   263 [+ or -] 173 pg/mL
TNF-[Alpha]                12 [+ or -] 55 pg/mL
CD3                     1,380 [+ or -] 432 [micro]L
CD4                       837 [+ or -] 297/[micro]L
CD8                       451 [+ or -] 176/[micro]L
OK-DR                     317 [+ or -] 127/[micro]L
CD25                      119 [+ or -] 57/[micro]L
CD16                      183 [+ or -] 110/[micro]L
CD19                      228 [+ or -] 118/[micro]L
CD11b                     216 [+ or -] 176/[micro]L
CD8+/CD56+ NK subset      134 [+ or -] 113/[micro]L

Abbreviations: IFN, interferon; IL, interleukin; sICAM-1,
soluble intercellular adhesion molecule 1; sIL, soluble
IL-1 receptor antagonist; TGF-[[Beta].sub.2], transforming growth
factor [[Beta].sub.2]; TNF-[Alpha], tumor necrosis factor [Alpha].

Determination of lymphocyte subpopulations. Lymphocyte subpopulations were determined as described previously (38). The mean [+ or -] 1 SD of the absolute lymphocyte count in 40 healthy controls was 1,804 [+ or -] 576/[micro]L. Other values are given in Table 1. The following panel of antibodies was used: CD3 (OKT3, pan T lymphocytes); CD4 (OKT4, helper/inducer T lymphocyte subset); CD8 (suppressor/cytotoxic T lymphocyte subset); OK-DR (MHC class II positive T and B lymphocytes, monocytes); CD25 (OKT26a, IL-2 receptor positive T lymphocytes); CD16 [OK-NK, natural killer (NK) cells]; CD19 (OKB19, B lymphocytes); CD11b (OKM1, monocytes, granulocytes, NK cells); and CD56 (NK cell subset), all from Ortho (Raritan, NJ, USA). Ten micro-liters of mononuclear antibody were added to 100 [micro]L of whole blood and incubated for 30 min at 4 [degrees] C. Erythrocytes were lysed with [NH.sub.4]Cl. The cells were washed and incubated with 50 [micro]L fluorescein isothyocyanate-conjugated goat-anti-mouse Ig (Medac, Hamburg, Germany) for another 30 min at 4 [degrees] C, washed again, and analyzed with an Ortho Cytoron flow cytometer using the same lymphocyte window for all patients. CD8+/CD56+ NK cell subsets were determined using double fluorescence flow cytometry with a FACScan flow cytometer (Becton Dickinson, Sunnyvale, CA, USA). The mean [+ or -] 1 SD range of the CD4/CD8 ratio was 2.0 [+ or -] 0.6.

Mitogen stimulation and mixed lymphocyte culture. Mononuclear cells obtained from heparinized blood were adjusted to 1 x [10.sup.6] cells/mL in culture medium TC-199 (Gibco, Grand Island, NY, USA) containing 20% heat-inactivated human AB-serum, 20 mM/L HEPES buffer, 100 U/mL penicillin, and 100 [micro]g/mL streptomycin. We tested in vitro stimulation of lymphocytes using pokeweed mitogen (PWM; Gibco, Paisley, Scotland), concanavalin A (Con A; Pharmacia, Uppsala, Sweden), phytohemagglutinin (PHA; Wellcome, Dartford, UK), or OKT3 mAb (anti-CD3; Ortho) in three different concentrations. We assessed the mixed lymphocyte culture (MLC) response using allogeneic MHC-incompatible stimulator cells pooled from three healthy donors. We added 100 [micro]L of irradiated pooled allogeneic stimulator cells ([10.sup.6] cells/mL) to wells of a microtray. All cultures were performed in triplicate by standard methods. Mitogen stimulation assays were incubated at 37 [degrees] C for 3 days and MLCs for 6 days. The cultures were pulsed with 20 [micro]L [sup.3]H-thymidine (1 mCi/mL), harvested after an additional 16 hr, and the incorporation of [sup.3]H-thymidine was measured. We calculated relative reponses (RR) as counts per minute of patient lymphocytes cultured with mitogen minus counts per minute of patient lymphocytes in medium, divided by counts per minute of control lymphocytes cultured with mitogen minus counts per minute of control lymphocytes in medium. The maximum RR of each mitogen was used for statistical analysis. Based on control measurements in 52 healthy individuals, an RR [is less than] 0.5 was considered abnormally low.

Determination of plasma neopterin. Plasma neopterin was measured initially with the neopterin-RIAcid assay and since 1995 with the Neopterin ELISA (Brahms, Berlin, Germany). Based on control measurements in 70 healthy individuals, we considered [is greater than] 15 nmol/L abnormally high for both tests (54).

Enzyme immunoassay for determination of anti-Ig activities. Anti-Ig autoantibodies were determined as previously described (54). We coated 96-well microtiter plates (Nunc, Roskilde, Denmark) at 37 [degrees] C for 16 hr with either 0.5 [micro]g/well of human IgG-Fab (ICN Biochemicals, Costa Mesa, CA, USA) or IgG-F(ab')2 fragments (Dianova). Uncoated sites were blocked for 3 hr at 37 [degrees] C with 1% phosphate-buffered saline-bovine serum albumin.

To determine IgG-anti-Fab and IgG-anti-F(ab')2 activities, 50 [micro]L of 1:64 diluted test serum was added; to determine IgA-anti-Fab and IgA-anti-F(ab')2 activities, 50 mL of 1:32 diluted test serum was added; and to determine IgM-anti-Fab and IgM-anti-F(ab')2 activities, 50 mL of 1:16 diluted test serum was added to the Fab- or F(ab')2-coated wells in the first step. In the second step, the reaction was developed with 50 [micro]L of alkaline phosphatase-conjugated goat antibodies specific for the Fc fragments of IgG, IgA, or IgM molecules (Dianova; working dilutions 1:5000). In all assays phosphate-buffered saline-Tween 0.05% was used as washing buffer and p-nitrophenyl phosphate disodium solution (Sigma Chemical Co., St. Louis, MO, USA) as substrate. All incubation steps with test sera and antibodies were performed at 22 [degrees] C for 1 hr. After each step the plates were washed four times with washing buffer. The optical density (OD) was measured ([+ or -] SEM) at 405 nm using a 340 ATTC Microplate Reader (SLT, Crailsheim, Germany).

Determination of PCP, PCBs, HCB, and HCHs in blood. Blood levels of PCP, PCBs, HCB, and HCHs were determined in the laboratory of K. Bauer (Saarbrucken, Germany) using gas chromatography (Hewlett Packard-GC 5890; Hewlett Packard, Palo Alto, CA, USA). Reference blood levels were determined by calculating the 95% quantile in 2941 randomly selected individuals who did not have a history of exposure to the chemicals.

Statistical analysis. Spearman rank correlation, Wilcoxon signed-rank test, and Fisher's exact test were applied using SPSS (Chicago, IL, USA). Adjustment for multiple testing was done according to the method of Bonferroni.

Results

Most patients were exposed to several of the investigated chemicals as indicated by increased blood levels of these chemicals above background (Table 2). Background blood levels were determined by calculating the 95% quantile in 2,941 randomly selected individuals who did not have a history of exposure to the chemicals. Means and ranges of PCB 101, PCB 138, PCB 153, PCB 180, HCH-[Beta], HCH-[Gamma], and HCB blood levels in patients with PCP blood levels [is less than or equal to] 10 [micro]g/L are shown in Table 2. The blood levels of many compounds were correlated with one another, indicating multiple exposure (Table 3).

Table 2. Number and percentage of patients with PCB, HCB, or HCH blood
levels above background.

                        No. of patients with
                         blood level above     Mean     5% Quantile
Background level           background (%)      blood        of
of chemical (ng/L)(a)        (n = 141)         level    blood level

PCB 28 < 10                    1 (1)
PCB 52 < 10                    1 (1)
PCB 101 < 100                  0                 31.4       13.0
PCB 138 < 500                 98 (70)           710.1      269.0
PCB 153 < 600                111 (79)          1025.1      389.0
PCB 180 < 300                107 (76)           599.1      141.0
HCB < 1,000                   60 (43)          1109.4      228.7
HCH-[Alpha] <10                0               < 10
HCH-[Beta] <350               13 (9)            256.2      101.0
HCH-[Gamma] <70                6 (4)             26.9       11.0

                        95% Quantile
Background level             of
of chemical (ng/L)(a)   blood level

PCB 28 < 10
PCB 52 < 10
PCB 101 < 100                66.0
PCB 138 < 500              1444.0
PCB 153 < 600              2221.0
PCB 180 < 300              1066.0
HCB < 1,000                2973.7
HCH-[Alpha] <10
HCH-[Beta] <350             513.5
HCH-[Gamma] <70              54.9

All patients analyzed had a PCP blood level [is less than] 10
[micro]g/L.

(a) The 95% quantile was defined in 2,941 randomly selected
individuals who did not have a history of exposure to the chemical.
Table 3. Cross-associations (Spearman rank correlations; r) of PCB
101, PCB 138, PCB 153, PCB 180, HCB, PCP, HCH-[Beta], and
HCH-[Gamma] blood levels in 141 patients.

               PCB 101      PCB 138      PCB 153     PCB 180

PCB 138        0.247(**)
PCB 153        0.183(*)     0.959(##)
PCB 180        0.201(*)     0.827(##)   0.828(##)
HCB            0.103        0.506(##)   0.473(##)   0.334(##)
PCP            0.166        0.082       0.079       0.051
HCH-[Beta]     0.009        0.471(##)   0.454(##)   0.347(##)
HCH-[Gamma]   -0.039       -0.008       0.007       0.004

              HCB          PCP    HCH-[Gamma]

PCB 138
PCB 153
PCB 180
HCB
PCP           0.315(##)
HCH-[Beta]    0.543(##)   0.003
HCH-[Gamma]   0.064       0.154      0.152

All patients analyzed had a PCP blood level [is less than] 10
[micro]g/L.

(*) p [is less than] 0.05; (**) p [is less than] 0.01; (##) p [is
less than] 0.0001.

We found only weak dose-response relationships between blood levels of PCBs, HCHs, or HCB with cellular and humoral immune parameters (Table 4). PCBs were weakly associated with in vitro lymphocyte stimulation and the numbers of lymphocyte subpopulations in the blood, as well as titers of different autoantibody types against immunoglobulin components, whereas HCH-[Beta] (Spearman rank correlation, vs. IL-2: r = 0.182, p = 0.040; vs. IL-10: r = 0.190; p = 0.032), HCH-[Gamma] (Spearman rank correlation, vs. IL-1[Beta]: r = -0.336, p = 0.024), and HCB (Spearman rank correlation, vs. IL-6: r = -0.189, p = 0.036; vs. sIL-1RA: r = 0.197, p = 0.029) were weakly associated with plasma levels of cytokines and cytokine receptor antagonists. The most prominent finding was a strong negative association between HCB and IFN-[Gamma] blood levels (Spearman rank correlation: r = -0.357, p [is less than] 0.0001), indicating that HCB has a significant impact on Th1 lymphocytes (Table 4).

Table 4. Association (Spearman rank correlations) of PCB 101, PCB 138,
PCB 153, PCB 180, HCB, HCH-[Beta], and HCH-[Gamma] plasma levels with
numbers of lymphocyte subpopulations, in vitro lymphocyte response,
plasma cytokine levels, and immunoglobulin autoantibodies in 141
patients.

                             PCB 101            PCB 138
                              p (r)              p (r)

CD4/CD8                         NS                 NS
CD4/[micro]L              0.017 (0.208)            NS
CD16/[micro]L                   NS                 NS
CD25/[micro]L             0.029 (0.191)      0.043 (-0.177)
CD8/56/[micro]L           0.023 (-0.495)           NS
CD11b/[micro]L                  NS                 NS
PHA (RR)                        NS                 NS
CD3 mab (RR)                    NS                 NS
IL-1[Beta]                      NS                 NS
IL-2                            NS                 NS
IL-6                            NS                 NS
IL-10                           NS                 NS
INF-[Gamma]                     NS                 NS
TGF-[Beta]2                     NS           0.039 (0.194)
sIL-1RA                         NS                 NS
IgA-anti-Fab                    NS                 NS
IgM-anti-Fab                    NS           0.004 (-0.271)
IgM-anti-[F(ab').sub.2]         NS           0.021 (-0.218)
GGT (U/mL)                      NS           0.009 (0.238)

                             PCB 153            PCB 180
                              p (r)              p (r)

CD4/CD8                         NS                 NS
CD4/[micro]L                    NS                 NS
CD16/[micro]L                   NS           0.049 (0.172)
CD25/[micro]L             0.036 (-0.183)           NS
CD8/56/[micro]L                 NS                 NS
CD11b/[micro]L                  NS                 NS
PHA (RR)                  0.029 (-0.192)     0.018 (-0.207)
CD3 mab (RR)              0.047 (-0.176)           NS
IL-1[Beta]                      NS                 NS
IL-2                            NS                 NS
IL-6                            NS                 NS
IL-10                           NS                 NS
INF-[Gamma]                     NS                 NS
TGF-[Beta]2                     NS           0.035 (0.199)
sIL-1RA                         NS                 NS
IgA-anti-Fab                    NS           0.021 (0.219)
IgM-anti-Fab              0.001 (-0.307)     0.004 (-0.272)
IgM-anti-[F(ab').sub.2]   0.006 (-0.256)     0.041 (-0.193)
GGT (U/mL)                0.017 (0.217)      0.050 (0.179)

                                 HCB             HCH-[Beta]
                                p (r)              p (r)

CD4/CD8                           NS                 NS
CD4/[micro]L                      NS                 NS
CD16/[micro]L                     NS                 NS
CD25/[micro]L                     NS                 NS
CD8/56/[micro]L                   NS                 NS
CD11b/[micro]L                    NS                 NS
PHA (RR)                          NS                 NS
CD3 mab (RR)                      NS                 NS
IL-1[Beta]                        NS                 NS
IL-2                              NS           0.040 (0.182)
IL-6                        0.036 (-0.189)           NS
IL-10                             NS           0.032 (0.190)
INF-[Gamma]               0.0001(a) (-0.357)         NS
TGF-[Beta]2                       NS                 NS
sIL-1RA                     0.029 (0.197)            NS
IgA-anti-Fab                      NS                 NS
IgM-anti-Fab                      NS                 NS
IgM-anti-[F(ab').sub.2]           NS                 NS
GGT (U/mL)                        NS           0.016 (0.218)

                            HCH-[Gamma]
                              p (r)

CD4/CD8                   0.035 (-0.183)
CD4/[micro]L                    NS
CD16/[micro]L                   NS
CD25/[micro]L                   NS
CD8/56/[micro]L                 NS
CD11b/[micro]L            0.015 (0.366)
PHA (RR)                        NS
CD3 mab (RR)                    NS
IL-1[Beta]                0.024 (-0.336)
IL-2                            NS
IL-6                            NS
IL-10                           NS
INF-[Gamma]                     NS
TGF-[Beta]2                     NS
sIL-1RA                         NS
IgA-anti-Fab                    NS
IgM-anti-Fab                    NS
IgM-anti-[F(ab').sub.2]         NS
GGT (U/mL)                      NS

Abbreviations: GGT, [Gamma]-glutamyl transpeptidase; NS, not
significant. Only p-values [is less than] 0.05 are listed. p-Values
were calculated using the Spearman rank correlation test. Adjustment
for multiple testing was done according to the method of Bonferroni.
All patients analyzed had a PCP blood level of [is less than] 10
[micro]g/L.

(a) Significant (p [is less than] 0.05) after adjustment for multiple
testing (analyzed parameters; n = 38).

When we calculated the frequency of individuals with impaired (below the mean -1 SD level) immune parameters in relation to blood levels above the mean, there were few associations that remained significant after adjustment for multiple testing (n = 38 analyzed parameters). Patients with HCB blood levels above the mean of 1,109 ng/L more often had undetectable IFN-[Gamma] blood levels than patients below the mean (23/52 vs. 11/72; Fisher's exact test: p = 0.0005). Patients with increased PCB 138 ([is greater than] 710 ng/L) more frequently had undetectable IL-4 blood levels than patients with PCB 138 below the mean (29/47 vs. 23/78; Fisher's exact test: p = 0.0007), and patients with increased PCB 101 ([is greater than] 31 ng/L) more often had low DR+ cell counts in the blood ([is less than] 190/[micro]L) than patients with PCB 101 below the mean (12/50 vs. 2/81; Fisher's exact test: p = 0.0002).

To assess possible cumulative effects, we compared patients who had blood levels of all compounds below background with patients who had blood levels of all compounds above background. Patients with low or absent blood levels of the chemicals studied had higher T lymphocyte counts (CD3/[micro]L: 1,772 [+ or -] 606 vs. 1,297 [+ or -] 496; p = 0.051), higher IFN-[Gamma] plasma levels (IFN-[Gamma]: 638 [+ or -] 737 pg/mL vs. 178 [+ or -] 313 pg/mL; p = 0.016), and lower GGT plasma levels ([Gamma]-glutamyl transpeptidase; 8 [+ or -] 2 U/mL vs. 15 [+ or -] 9 U/mL; p = 0.055), which provides some evidence for a cumulative effect of several weakly active compounds (Table 5).

Table 5. Immune and enzymatic parameters (means [+ or -] 1 SD) of
patients with blood levels of all compounds below background versus
immune and enzymatic parameters of patients with blood levels of all
compounds above background.

                               Patients with blood
                                  levels of all
                                    compounds

                                  Below background
Parameter                             (n = 9)

Lymphocytes/[micro]L            2,357 [+ or -] 897
CD3/[micro]L                    1,772 [+ or -] 648
CD4/[micro]L                    1,120 [+ or -] 539
CD8/[micro]L                      537 [+ or -] 207
CD16/[micro]L                     259 [+ or -] 279
CD19/[micro]L                     305 [+ or -] 157
CD25/[micro]L                     128 [+ or -] 62
DR/[micro]L                       384 [+ or -] 127
Con A (RR)                        1.2 [+ or -] 0.9
PHA (RR)                          2.0 [+ or -] 2.9
PWM (RR)                          1.7 [+ or -] 1.8
CD3 mab (RR)                      7.5 [+ or -] 13.7
MLC (RR)                          2.1 [+ or -] 1.6
Neopterin (nmol/L)                 21 [+ or -] 37
IL-1[Alpha] (pg/mL)                 1 [+ or -] 1
IL-1[Beta] (pg/mL)                  1 [+ or -] 1
sIL-1RA (pg/mL)                   431 [+ or -] 145
IL-2 (pg/mL)                       10 [| or -] 10
sIL-2R (pg/mL)                  1,919 [+ or -] 1,422
IL-3 (pg/mL)                       68 [+ or -] 146
IL-4 (pg/mL)                       87 [+ or -] 247
IL-6 (pg/mL)                      216 [+ or -] 442
sIL-6R (pg/mL)                 35,781 [+ or -] 17,854
IL-8 (pg/mL)                       49 [+ or -] 12
IL-10 (pg/mL)                       3 [+ or -] 5
TNF-[Alpha] (pg/mL)                41 [+ or -] 72
TGF-[[Beta].sub.2] (pg/mL)          2 [+ or -] 2
IFN-[Gamma] (pg/mL)               638 [+ or -] 737
sICAM-1 ([micro]g/mL)             185 [+ or -] 42
SGOT (U/mL)                        10 [+ or -] 7
GPT (U/mL)                         14 [+ or -] 10
GGT (U/mL)                          8 [+ or -]  3
IgA-anti-Fab (OD)                 0.1 [+ or -] 0.1
IgA-anti-[F(ab').sub.2] (OD)      0.1 [+ or -] 0.1
IgG-anti-Fab (OD)                 0.4 [+ or -] 0.4
IgG-anti-[F(ab').sub.2] (OD)      0.7 [+ or -] 0.4
IgM-anti-Fab (OD)                 0.2 [+ or -] 0.1
IgM-anti-[F(ab').sub.2] (OD)      0.1 [+ or -] 0.1

                                  Above background
Parameter                             (n = 40)            P

Lymphocytes/[micro]L            1,868 [+ or -] 824        NS
CD3/[micro]L                    1,297 [+ or -] 502      0.051
CD4/[micro]L                      788 [+ or -] 323        NS
CD8/[micro]L                      466 [+ or -] 250        NS
CD16/[micro]L                     243 [+ or -] 143        NS
CD19/[micro]L                     250 [+ or -] 234        NS
CD25/[micro]L                     114 [+ or -] 113        NS
DR/[micro]L                       360 [+ or -] 351        NS
Con A (RR)                        1.1 [+ or -] 0.5        NS
PHA (RR)                          0.9 [+ or -] 0.5        NS
PWM (RR)                          1.4 [+ or -] 1.0        NS
CD3 mab (RR)                      3.1 [+ or -] 6.6        NS
MLC (RR)                          1.4 [+ or -] 2.0        NS
Neopterin (nmol/L)                  8 [+ or -] 4          NS
IL-1[Alpha] (pg/mL)                 1 [+ or -] 1          n.s
IL-1[Beta] (pg/mL)                       0                NS
sIL-1RA (pg/mL)                   646 [+ or -] 704        NS
IL-2 (pg/mL)                       12 [+ or -] 11         NS
sIL-2R (pg/mL)                  2,192 [+ or -] 2,021      NS
IL-3 (pg/mL)                       16 [+ or -] 26         NS
IL-4 (pg/mL)                        5 [+ or -] 11         NS
IL-6 (pg/mL)                       62 [+ or -] 112        NS
sIL-6R (pg/mL)                 30,498 [+ or -] 14,369     NS
IL-8 (pg/mL)                       37 [+ or -] 43         NS
IL-10 (pg/mL)                      14 [+ or -] 48         NS
TNF-[Alpha] (pg/mL)                78 [+ or -] 245        NS
TGF-[[Beta].sub.2] (pg/mL)         12 [+ or -] 20         NS
IFN-[Gamma] (pg/mL)               178 [+ or -] 318      0.016
sICAM-1 ([micro]g/mL)             348 [+ or -] 146        NS
SGOT (U/mL)                        10 [+ or -] 3          NS
GPT (U/mL)                         14 [+ or -] 7          NS
GGT (U/mL)                         15 [+ or -] 10       0.055
IgA-anti-Fab (OD)                 0.2 [+ or -] 0.1        NS
IgA-anti-[F(ab').sub.2] (OD)      0.2 [+ or -] 0.2        NS
IgG-anti-Fab (OD)                 0.3 [+ or -] 0.3        NS
IgG-anti-[F(ab').sub.2] (OD)      0.6 [+ or -] 0.4        NS
IgM-anti-Fab (OD)                 0.1 [+ or -] 0.1        NS
IgM-anti-[F(ab').sub.2] (OD)      0.1 [+ or -] 0.1        NS

Abbreviations: GPT, glutamic pyruvic transaminase; NS, not
significant; SGOT, serum glutamic--oxaloacetic transaminase; sICAM-1,
soluble intercellular adhesion molecule 1. All patients analyzed had a
PCP blood level [is less than] 10 [micro]g/L. Background levels: PCB
138 [is less than] 500 ng/L, PCB 153 [is less than] 600 ng/L, PCB 180
[is less than] 300 ng/L, HCB [is less than] 1,000 ng/L.

We studied 12 patients twice during a mean time interval of 936 days. HCH-[Gamma] blood levels decreased from a mean of 36.3 ng/L to a mean of 19.2 ng/L (p = 0.033), whereas the mean PCB 153 blood level increased from 857.0 ng/L to 1024.4 ng/L (p = 0.050). The blood levels of the other chemicals were not significantly different between the two measurements, suggesting rather constant exposure (Table 6).

Table 6. Blood levels (mean [+ or -] 1 SD) of PCB 101, PCB 138, PCB
153, PCB 180, HCB, HCH-[Beta], and HCH-[Gamma] in 12 patients who were
tested twice (mean time interval, 936 days).

                      First determination     Second determination

PCB 101 (ng/L)         46.5 [+ or -] 26.7       28.9 [+ or -] 16.4
PCB 138 (ng/L)        598.0 [+ or -] 160.1     700.5 [+ or -] 315.9
PCB 153 (ng/L)        857.0 [+ or -] 261.2    1024.4 [+ or -] 518.1
PCB 180 (ng/L)        437.0 [+ or -] 191.5     474.0 [+ or -] 296.9
HCB (ng/L)           1240.8 [+ or -] 1150.4    879.4 [+ or -] 461.9
HCH-[Beta] (ng/L)     188.0 [+ or -] 66.4      186.0 [+ or -] 58.6
HCH-[Gamma] (ng/L)     36.3 [+ or -] 25.6       19.2 [+ or -] 9.2

                       P

PCB 101 (ng/L)       0.221
PCB 138 (ng/L)       0.084
PCB 153 (ng/L)       0.050
PCB 180 (ng/L)       0.610
HCB (ng/L)           0.155
HCH-[Beta] (ng/L)    0.625
HCH-[Gamma] (ng/L)   0.033

p-Values were calculated using the Wilcoxon signed-ranks test. All
patients analyzed had a PCP blood level [is less than] 10 [micro]g/L.

Discussion

PCP, PCBs, HCB, and HCHs are incorporated into human tissues transdermally or via inhalation, or they can become part of the food chain and accumulate in the body, especially in lipophilic body tissues. During periods of starvation or after cessation of exposure, the chemicals are redistributed to the blood from lipophilic tissues. Long-term, low-dose exposure is suspected to cause clinical symptoms, such as chronic infections of the upper respiratory tract, general fatigue, and neurotoxicity.

In this study we analyzed individuals with a documented history of PCB, HCB, and HCH exposure who had PCP blood levels in the background range of [is less than or equal to] 10 [micro]g/L. Because PCP was shown in previous studies to be strongly associated with humoral and cellular dysfunction, we excluded individuals with PCP blood levels [is greater than] 10 [micro]g/L from the analysis (38,49). The blood levels of PCBs, HCB, and HCHs were often associated with one another, suggesting simultaneous exposure, making it difficult to dissociate the impact of individual compounds. The observed positive and negative associations of cellular and humoral immune parameters with blood levels of PCBs, HCB, and HCHs were relatively weak, with the exception of a strongly negative association of IFN-[Gamma] with HCB. This finding indicates that HCB has a significant impact on Th1 lymphocytes in vivo. IFN-[Gamma], which is produced by Th1 lymphocytes, is involved in the induction of cellular immune responses against antigens such as viruses by activating NK cells, monocytes/macrophages, and granulocytes, and in humoral immune responses by increasing the immunoglobulin secretion of plasma cells. Impaired IFN-[Gamma] production might favor infections. These data are in agreement with reports that oral exposure to HCB at concentrations of 150 and 450 mg/kg food for 6 weeks suppressed NK activity in rat lungs in a dose-related manner (56). Immunotoxic effects of HCB on the pathogenesis of systemic, pneumonic, and hepatic viral infections were described in the mouse (57). Moreover, HCB has been reported to suppress humoral and cell-mediated immunity to protozoan (malaria and leishmania) infections and to tumor cell challenges in the mouse (58). Gram-negative endotoxin (Salmonella typhosa) sensitivity in PCB- and HCB-treated mice was increased 5.2- and 32-fold, respectively (59). Mice fed PCB or HCB for 3-6 weeks and inoculated with Plasmodium berghei had decreased survival times (59). Workers exposed to HCB showed an impaired lytic activity of neutrophils in the presence of Candida albicans and Candida pseudotropicalis (60). It is noteworthy that NK cells seem to have a role in the pathogenesis of chronic fatigue syndrome (CFS) (61) and that patients with CFS showed elevated HCB serum levels (62). The incidence of HCB contamination ([is greater than] 2.0 ppb) was 45% in a CFS group compared with 21% in a non-CFS control group (p [is less than] 0.05) (62).

The impact of HCB on humoral immune responses is controversial, especially concerning autoimmune responses. Our finding of a positive association of IgA-anti-Fab serum autoantibodies and the lack of an association of IgG-anti-Fab and IgG-anti-F(ab')2 with HCB blood levels are in partial agreement with observations describing dose-dependent increases of serum levels of IgM, IgA, and autoantigen-specific IgM as well as unchanged levels of IgG and IgG autoantibody levels in rats given HCB in their diet (13,63). The negative associations of IgM-anti-Fab and IgM-anti-F(ab')2 with PCBs in our patients vary with findings in animals on IgM responses against single-stranded DNA, native DNA, rat IgG (representing rheumatoid factor), and bromelain-treated mouse erythrocytes (13). However, others reported that antibody synthesis to sheep red blood cells was significantly depressed in PCB- and HCB-treated mice, and serum IgA concentrations were consistently 40-80 mg/dL lower than controls (59). The ability of HCB to elevate serum antibody levels against autoantigens but not against foreign antigens suggests that HCB does not act as a polyclonal B cell activator (13). HCB activates rat splenic B-1 cells committed to produce autoantibodies associated with systemic autoimmune diseases (13,64). It is of interest that increased IgG and IgM serum levels were reported in HCB-exposed workers (65). However, the workers were not examined for the presence of autoimmune phenomena.

The weak associations of PCBs, HCB, and HCHs with immunologic abnormalities described herein are in stark contrast to the striking abnormalities observed in individuals with high blood levels of PCP (38,49). The clinical relevance of HCB-associated suppression of IFN-[Gamma] awaits further clarification.

REFERENCES AND NOTES

(1.) Cleseri LS. Case history: PCBs in the Hudson River. In: Introduction to Environmental Toxicology (Guthrie FE, Perry JJ, eds). New York:Elsevier/North Holland, 1980;227-235.

(2). Fishbein L. Toxicity of chlorinated biphenyls. Annu Rev Pharmacol 14:139-156 (1974).

(3). Kimbrough R. Human health effects of PCBs and PBBs. Annu Rev Pharmacol Toxicol 27:87-111 (1987).

(4). Pott F, KrooB J, Kohler M, Stolz P. Bremer Umweltinstitut. In: Gift im Holz. Reihe: Umwelt & Arbeit. Bremen, Germany:Bremer Umweltinstitut e. V., 1994;33.

(5.) Zheng T, Holford TR, Mayne ST, Tessari J, Owens PH, Zahm SH, Zhang B, Dubrow R, Ward B, Carter D, et al. Environmental exposure to hexachlorobenzene (HCB) and risk of female breast cancer in Connecticut. Cancer Epidemiol Biomark Prev 8:407-411 (1999).

(6.) Svensson B-G, Hallberg T, Nilsson A, Schutz A, Hagmar L. Parameter of immunological competence in subjects with high consumption of fish contaminated with persistent organochlorine compounds. Int Arch Occup Environ Health 65:351-358 (1994).

(7.) Nelson N. Polychlorinated biphenyls: environmental impact. Environ Res 5:253-362 (1972).

(8). Zitco V, Choi PMK. PCB and Other Industrial Halogenated Hydrocarbons in the Environment. Fisheries Research Board of Canada, Technical Report 272. St. Andrews, New Brunswick, Canada:Biological Station, Fisheries Research Board of Canada, 1971;2-54.

(9). Higuchi K, ed. PCB Poisoning and Pollution. New York:Academic Press, 1976.

(10). Buckley JL, ed. National Conference on Polychlorinated Biphenyls. Washington DC:U.S. Environmental Protection Agency, 1976.

(11). Yoo BS, Jung KH, Hana SB, Kim HM. Apoptosis-mediated immunotoxicity of polychlorinated biphenyls (PCBs) in murine splenocytes. Toxicol Lett 91:83-89 (1997).

(12). Hoffman DJ, Melancon MJ, Klein PN, Rice CP, Eisemann JD, Hines RK, Spann JW, Pendleton GW. Developmental toxicity of PCB 126 (3,3',4,4',5-pentachlorobiphenyl) in nestling American kestrels (Falco sparverius). Fundam Appl Toxicol 34:188-200 (1996).

(13). Schielen P, Van Der Pijl A, Bleumink R, Pieters RH, Seinen W. Local popliteal lymph node reactions to hexachlorobenzene and pentachlorobenzene: comparison with systemic effects. Immunopharmacology 31:171-181 (1996).

(14). De Swart RL, Ross PS, Vos JG, Osterhaus AD. Impaired immunity in harbour seals (Phoca vitulina) fed environmentally contaminated herring. Vet Q(suppl 3):S127-128 (1996).

(15). Ross PS, Van Loveren H, De Swart RL, van der Vliet H, de Klerk A, Timmermann HH, van Binnendijk R, Brouwer A, Vos JG, Osterhaus AD. Host resistance to rat cytomagalovirus (RCMV) and immune function in adult rats fed herring from contaminated Baltic Sea. Arch Toxico1 70:661-671 (1996).

(16). Arnold DL, Bryce F, McGuire PF, Stapley R, Tanner JR, Wrenshall E, Mes J, Fernie S, Tryphonas H, Hayward S, et al. Toxicological consequences of aroclor 1254 ingestion by female rhesus (Macaca mulatta) monkeys. Part 2. Reproduction and infant finding. Food Chem Toxicol 33:457-474 (1995).

(17). Nakanishi Y, Nomoto Y, Matsuki A, Kunitake R, Hara N. Effect of polychlorinated biphenyls and polychlorinated dibenzofurans on leukocyte in peripheral blood and bronchoalveolar lavage fluid. Fukuoka Igaku Zasshi 86:261-286 (1995).

(18). Lahvis GP, Wells RS, Kuehl DW, Stewart JL, Rhinehart HL, Via CS. Decreased lymphocyte responses in freeranging bottlanose dolphins (Tursiops truncatus) are associated with increased concentrations of PCBs and DDT in peripheral blood. Environ Health Perspect 103(suppl 4):67-72 (1995).

(19.) De Krey GK, Baecher-Steppan L, Fowles JR, Kerkvliet NI. Polychlorinated biphenyl-induced suppression of cytotoxic T lymphocyte activity: role of prostaglandin-E2. Toxicol Lett 74:211-220 (1994).

(20). Lai ZW, Kremer J, Gleichmann E, Esser C. 3,3',4,4'-tetrachlorobiphenyl inhibits proliferation of immature thymocytes in fetal thymus organ culture. Scand J Immunol 39:480-488 (1994).

(21). Arkoosh MR, Clemons E, Myers M, Casillas E. Suppression of B-cell mediated immunity in juvenile chinook salmon (Oncorhynchus tshawytscha) after exposure to either a polycyclic aromatic hydrocarbon or to polychlorinated biphenyls. Immunopharmacol Immunotoxicol 16:293-314 (1994).

(22). De Krey GK, Hollingshead NC, Kerkvliet NI, Smith BB. Suppression of prolactin and cytotoxic T-lymphocyte activity in PCB-treated mice. Int J Immunopharmacol 16:251-257 (1994).

(23). Harper N, Howie L, Connor K, Dickerson R, Safe S. Immunosuppressive effects of highly chlorinated biphenyls and diphenyl ethers on T-cell dependent and independent antigens in mice. Toxicology 85:123-135 (1993).

(24.) Esser C, Welzel M Ontogenic development of murine fetal thymocytes is accelerated by 3,3',4,4'-tetrachlorobiphenyl. Int J Immunopharmacol 15:841-852 (1993).

(25.) De Krey GK, Baecher-Steppan L, Deyo JA, Smith B, Kerkvliet NI. Polychlorinated biphenyl-induced immune suppression: castration, but not adrenalectomy or RU 38486 treatment, partially restores the suppressed cytotoxic T lymphocyte response to alloantigen. J Pharmacol Exp Ther 267:308-315 (1993).

(26.) Harper N, Connor K, Safe S. Immunotoxic potencies of polychlorinated biphenyl (PCB), dibenzofuran (PCDF) and dibenzo-p-dioxin (PCDD) congeners in C57BL/6 and DBA/2 mice. Toxicology 80:217-227 (1993).

(27.) Tryphonas H, Luster MI, White KL Jr, Naylor PH, Erdos MR, Burleson GR, Germolec D, Hodgen M, Hayward S, Arnold DL. Effect of PCB (Aroclor 1254) on non-specific immune parameters in rhesus (Macaca mulatta) monkeys. Int J Immunopharmacol 13:639-648 (1991).

(28). Kerkvliet NI, Baecher-Steppan L, Smith BB, Youngberg JA, Henderson MC, Buhler DR. Role of the Ah locus in suppression of cytotoxic T lymphocyte activity by halogenated aromatic hydrocarbons (PCBs and TGDD): structure-activity relationship and effects in C57BI/6 mice congenic at the Ah locus. Fundam Appl Toxicol 14:532-541 (1990).

(29.) Meera P, Rao PR, Shanker R, Tripanthi O. Immunomodulatory effects of gamma-HCH (lindane) in mice. Immunopharmacol Immunotoxicol 14:261-282 (1992).

(30). Mandal A, Chakrabort S, Lahiri P. Hematological changes produced by lindane (gamma-HCH) in six species of birds. Toxicology 40:103-111 (1986).

(31.) Das SN, Paul BN, Saxena AK, Ray PK. Effect of in utero exposure to hexachlorocyclohexane on the developing immune system of mice. Immunopharmacol Immunotoxicol 12:293-310 (1990).

(32). Lang D, Mueller-Ruchholtz W. Human lymphocyte reactivity after in vitro exposure to technical and analytical grade pentachlorophenol. Toxicology 70:271-282 (1991).

(33.) Kerkvliet NI, Brauner JA, Matlock JP. Humoral immunotoxicity of polychlorinated diphenyl ethers, phenoxyphanols, dioxins and furans present as contaminants of technical grade pentachlorophenol. Toxicology 36:307-324 (1985).

(34.) Kerkvliet NI, Brauner JA, Baecher-Steppan L. Effects of dietary technical pentachlorophenol exposure on T cell, macrophage and natural killer cell activity in C57BI/6 mice. Int J Immunopharmacol 7:239-247 (1985).

(35). Exon JH, Koller LD. Effects of chlorinated phenols on immunity in rats. Int J Immunpharmacol 5:131-136 (1983).

(36). Blakely BR, Yole MJ, Brousseau P, Boermans H, Fournier M. Effect of pentachlorophenol on immune function. Toxicology 125:141-148 (1998).

(37). McConnachie PR, Zahalsky AC. Immunological consequences of exposure to pentachlorophenol. Arch Environ Health 46:249-253 (1991).

(38). Daniel V, Huber W, Bauer K, Opelz G. Impaired in-vitro lymphocyte responses in patients with elevated pentachlorophenol (PCP) blood levels. Arch Environ Health 50:287-292 (1995).

(39). Omara FO, Flipo D, Brochu C, Denizeau F, Brousseau P, Potworowski EP, Fournier M. Lack of suppressive effects of mixtures containing low levels of methylmercury (MeHg), polychlorinated dibenzo-p-dioxins (PCDDS), polychlorinated dibenzofurans (PCDFS), and aroclor biphenyls (PCBS) on mixed lymphocyte reaction, phagocytic, and natural killer cell activities of rat leukocytes in vitro. J Toxicol Environ Health 54:561-577 (1998).

(40). Fowles JR, Fairbrother A, Trust KA, Kerkvliet NI. Effects of Aroclor 1254 on the thyroid gland, immune function, and hepatic cytochrome P450 activity in mallards. Environ Res 75:119-129 (1997).

(41). Fernlof G, Gadhasson I, Pora K, Darnerud PO, Thuvander, A. Lack of effects of some individual polybrominated diphenyl ether (PBDE) and polychlorinated biphenyl (PCB) congeners on human lymphocyte functions in vitro. Toxicol Lett 90:189-197 (1997).

(42). Belpaeme K, Delbeke K, Zhu L, Kirsch-Volders M. PCBs do not induce DNA breakage in vitro in human lymphocytes. Mutagenesis 11:383-389 (1996).

(43.) Lai ZW, Griem P, Gleichmann E, Esser C. CD8 thymocytes derived from 3,3',4,4'-tetrachlorobiphenyl-exposed fetal thymi possess killing activity. Toxicol Appl Pharmacol 133:223-232 (1995).

(44.) Yu ML, Hsin JW, Hsu CC, Chan WC, Gu YL. The immunologic evaluation of the Yucheng children. Chemosphere 37:1855-1865 (1998).

(45). Nagayama J, Tsuji H, Iida T, Hirakawa H, Matsueda T, Okamura K, Hasegawa M, Sato K, Ma HY, Yanagawa T, et al. Postnatal exposure to chlorinated dioxins and related chemicals on lymphocyte subsets in Japanese breast-fed infants. Chemosphere 37:1781-1787 (1998).

(46.) Weisglas-Kuperus N, Sas TC, Koopman-Esseboom C, van der Zwan CW, De Ridder MA, Beishuizen A, Hooijkaas H, Sauer PJ. Immunologic effects of background prenatal and postnatal exposure to dioxins and polychlorinated biphenyls in Dutch infants. Pediatr Res 38:404-410 (1995).

(47.) Svensson BG, Hallberg T, Nilsson A, Schutz A, Hagmar L. Parameters of immunological competence in subjects with high consumption of fish contaminated with persistent organochlorine compounds. Int Arch Occup Environ Health 65:351-358 (1994).

(48). Lee T-P. The toxic effect of polychlorinated biphenyls. In: Principles and Practice of Immunotoxicology (Miller K, Turk JL, Nicklin S, eds). Oxford, UK:Blackwell Scientific Publications, 1992;242-250.

(49.) Daniel V, Huber W, Bauer K, Suesal C, Mytilineos J, Melk A, Conradt C, Opelz G. Association of elevated pentachlorophenol (PCP) blood levels with cellular and humoral immunodeficiencies. Arch Environ Health (in press).

(50). Ohnsorge P. Is it appropriate to consider wood preservative poisoning in the differential diagnosis of chronic recurrent respiratory tract infections? Laryngorhinootologie 5:131-136(1991).

(51.) Rodriguez-Pichardo A, Camacho F, Rappe C, Hansson M, Smith AG, Greig JB. Chloracne caused by ingestion of olive oil contaminated with PCDDs and PCDFs. Hum Exp Toxicol 10:311-322 (1991).

(52). Rogan WJ, Gladen BC. Neurotoxicology of PCBs and related compounds. Neurotoxicology 13:27-35 (1992).

(53.) Nakagawa R, Takahashi K. Studies on the application of residual PCBs, PCQs and PCDFs concentrations to Yusho diagnosis. Fukuoka Igaku Zasshi 82:280-294 (1991).

(54). Schafer AJ, Daniel V, Dreikorn K, Opelz G. Assessment of plasma neopterin in clinical kidney transplantation. Transplantation 41:454-459 (1986).

(55). Susal C, Lewin IV, Stanworth DR, Terness P, Daniel V, Oberg HH, Huth-Kuhne A, Zimmermann R, Opelz G. AntilgG autoantibodies in HIV-infected hemophilia patients. Vox Sang 62:224-229 (1992).

(56). Van Loveren H, Krajnc El, Rombout PJ, Blommaert FA, Vos JG. Effects of ozone, hexachlorobenzene, and bis(tri-n-butyltin)oxide on natural killer activity in the rat lung. Toxicol Appl Pharmacol 102:21-33 (1990).

(57). Carthew P, Edwards RE, Smith AG. Immunotoxic effects of hexachlorobenzene on the pathogenesis of systemic, pneumonic and hepatic virus infections in the mouse. Hum Exp Toxicol 9:403-411 (1990).

(58). Vos JG. Immunotoxicity of hexachlorobenzene. IARC Sci Publ 77:347-356 (1986).

(59). Loose LD, Pittman KA, Benitz KF, Silkworth JB, Mueller W, Coulston F. Environmental chemical-induced immune dysfunction. Ecotoxicol Environ Saf 2:173-198 (1978).

(60.) Queiroz ML, Quadros MR, Valadares MC, Silveira JP. Polymorphonuclear phagocytosis and killing in workers occupationally exposed to hexachlorobenzene. Immunopharmacol Immunotoxicol 20:447-454 (1998).

(61). Whiteside TL, Friberg D. Natural killer cells and natural killer cell activity in chronic fatigue syndrome. Am Med 105(3A):27S-34S (1998).

(62). Dunstan RH, Donohoe M, Taylor W, Roberts TK, Murdoch RN, Watkins JA, McGregor NR. A preliminary investigation of chlorinated hydrocarbons and chronic fatigue syndrome. Med J Aust 163:294-297 (1995).

(63.) Schielen P, Den Besten C, Vos JG, Van Bladeren PJ, Seinen W, Bloksm N. Immune effects of hexachlorobenzene in the rat: role of metabolism in a 13-week feeding study. Toxicol Appl Pharmacol 131:37--43 (1995).

(64.) Schielen P, Van Rodijnen W, Pieters RH, Seinen W. Hexachlorobenzene treatment increases the number of splenic B-1-like cells and serum autoantibody levels in the rat. Immunology 86:568-574 (1995).

(65). Queiroz ML, Bincoletto C, Perlingeiro RC, Guadros MR, Souza CA. Immunoglobulin levels in workers exposed to hexachlorobenzene. Hum Exp Toxicol 3:172-175 (1998).

Address correspondence to V. Daniel, Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305, D-60120 Heidelberg, Germany. Telephone: [phone]. Fax: [phone]. E-mail: Volker_Daniel@ med.uni-heidelberg.de

We acknowledge the skillful technical assistance of G. Schmeckenbecher, N. Cetinkaya, M. KutscheBauer, C. Hoffmann, R. Seemuth, and N. Schwind.

Received 31 March 2000; accepted 28 September 2000.

Volker Daniel,(1) Wolfgang Huber,(2) Klausdieter Bauer,(3) Caner Suesal,(1) Christian Conradt,(4) and Gerhard Opelz(1)

(1) Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany; (2) private Practice, Heidelberg-Wieblingen, Germany; (3) Labor PD Dr. K. Bauer, Saarbrucken, Germany; (4) Institute of Medical Biometry, University of Heidelberg, Heidelberg, Germany